For the quarter ending 2026-03-31, NUVB has $610,241K in assets. $290,677K in debts. $125,391K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 125,391 | 164,086 | 98,897 | 247,970 |
| Accounts receivable, net of allowance for credit loss of nil and nil | 22,723 | 16,076 | 8,323 | 2,693 |
| Inventory | 15,844 | 11,411 | 5,710 | 552 |
| Prepaid expenses and other current assets | 15,972 | 11,536 | 8,925 | 8,257 |
| Marketable securities | 408,338 | 365,125 | 450,148 | 359,752 |
| Interest receivable on marketable securities | 3,261 | 3,285 | 5,527 | 3,984 |
| Total current assets | 591,529 | 571,519 | 577,530 | 623,208 |
| Total property and equipment | - | 1,748 | - | - |
| Less accumulated depreciation and amortization | - | 1,184 | - | - |
| Property and equipment, net of accumulated depreciation of 1,260 and 1,184, respectively | 535 | 564 | 560 | 615 |
| Intangible assets, net of accumulated amortization of 2,315 and 1,856, respectively | 10,755 | 11,214 | 11,680 | 12,145 |
| Operating lease right-of-use assets | 3,598 | 3,918 | 4,329 | 4,641 |
| Other non-current assets | 3,824 | 7,607 | 7,462 | 6,616 |
| Total assets | 610,241 | 594,822 | 601,561 | 647,225 |
| Accounts payable | 22,435 | 9,479 | 15,360 | 22,419 |
| Current operating lease liabilities | 1,838 | 1,880 | 1,871 | 1,808 |
| Contract liabilities, current portion | 8,651 | 7,515 | 6,721 | 9,725 |
| Liability related to revenue interest financing agreement, current portion | 7,944 | 9,585 | 5,982 | 2,823 |
| Short-term borrowings | 5,790 | 5,724 | 5,618 | 5,583 |
| Warrant liability | 0 | 2,865 | 1,738 | 2,350 |
| Accrued expenses | 32,864 | 45,183 | 32,579 | 23,998 |
| Total current liabilities | 79,522 | 82,231 | 68,131 | 66,356 |
| Contract liabilities, net of current portion | 9,743 | 11,305 | 11,130 | 12,459 |
| Non-current operating lease liabilities | 2,199 | 2,543 | 2,970 | 3,399 |
| Non-current liability related to revenue interest financing agreement, net of deferred financing costs of 4,030 and 4,241, respectively | 151,886 | 145,819 | 144,621 | 142,780 |
| Long-term borrowings, net of deferred financing costs of 2,923 and 3,042, respectively | 47,327 | 47,208 | 47,089 | 46,974 |
| Total liabilities | 290,677 | 289,106 | 275,679 | 274,318 |
| Class a and class b common stock and additional paid in capital, 0.0001 par value per share 1,060,000,000 (class a 1,000,000,000, class b 60,000,000 shares authorized as of march 31, 2026 and december 31, 2025 respectively 347,693,331 (class a 346,693,331, class b 1,000,000) and 346,503,675 (class a 345,503,675, class b 1,00,000) shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 1,431,214 | 1,421,273 | 1,404,799 | 1,396,220 |
| Accumulated deficit | -1,109,973 | -1,115,370 | -1,078,778 | -1,022,986 |
| Accumulated other comprehensive income | -1,677 | -187 | -139 | -327 |
| Total stockholders' equity | 319,564 | 305,716 | 325,882 | 372,907 |
| Total liabilities and stockholders' equity | 610,241 | 594,822 | 601,561 | 647,225 |
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)